Diagnosekriterien bei Multipler Sklerose: ein Update

Widmung

Herrn Prof. Dr. med. W. Firnhaber zum 90. Geburtstag gewidmet.

Zusammenfassung

Neben der klinisch-neurologischen Untersuchung spielt auch die MRT in der Diagnostik und der Verlaufsbeurteilung der Multiplen Sklerose eine wesentliche Rolle. In dieser Übersicht werden die mit der 2017er-Revision der McDonald-Kriterien einhergehenden Änderungen erläutert und differenzialdiagnostische Aspekte, sog. „green flags“ und „red flags“, dargestellt.

Abstract

In addition to clinical neurological examination, MRI is of major importance in the diagnosis and assessment of the course of multiple sclerosis. In this overview, the changes associated with the current 2017 revision of the McDonald criteria are explained and differential diagnostic aspects, so-called green and red flags, are presented.

Schlüsselwörter

Multiple Sklerose - McDonald-Kriterien

Key words

multiple sclerosis - McDonald criteria

• Literatur

• 1 Brownlee W, Hardy TA, Fazekas F. et al. Diagnosis of multiple sclerosis: progress and challenges. Lancet 2017; 389: 1336-1346
• 2 Polman CH, Reingold SC, Banwell B. et al. Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria. Ann Neurol 2011; 69: 292-302
• 3 Thompson AJ, Banwell BL, Barkhof F. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17: 162-173
• 4 Kaunzner U, Al-Kawaz M, Gauthier S. Defining Disease Activity and Response to Therapy in MS. Curr Treat Opin Neurol 2017; 19: 20
• 5 Filippi M, Preziosa P, Banwell B. et al. Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. Brain 2019; 142: 1858-1875
• 6 Wattjes MP, Raab P. [Brain and spinal cord MRI in multiple sclerosis: an update]. Akt Neurol 2018; 45: 29-43
• 7 Hardy TA, Reddel SW, Barnett MH. et al. Atypical inflammatory demyelinating syndroms of the CNS. Lancet Neurol 2016; 15: 967-981
• 8 Miller DH, Weinshenker BG, Filippi M. et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008; 14: 1157-1174
• 9 Eckstein C, Saidha S, Levy M. A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis. J Neurol 2012; 259: 801-816
• 10 Traboulsee A, Simon JH, Stone L. et al. Revised recommendations of the consortium of MS centers task force for a standardized MRI protocol and clinical guidelines for the diagnosis and follow-up of multiple sclerosis. AJNR Am J Neuroradiol 2016; 37: 394-401
• 11 Alper G. Acute Disseminated Encephalomyelitis. J Child Neurol 2012; 27: 1408-1425
• 12 Banwell B, Ghezzi A, Bar-Or A. et al. Multiple Sclerosis in Children: Clinical Diagnosis, Therapeutic Strategies, and Future Directions. Lancet Neurol 2007; 6: 887-902
• 13 Padilha I, Fonseca A, Pettengill A. et al. Pediatric multiple sclerosis: from clinical basis to imaging spectrum and differential diagnosis. Pediatr Radiol 2020; 50: 776-792
• 14 Cortese R, Collorone S, Ciccarelli O. et al. Advances in brain imaging in multiple sclerosis. Ther Adv Neurol Disord 2019; 12: 1-15
• 15 Weidauer S, Wagner M, Nichtweiß M. Magnetic Resonance Imaging and Clinical Features in Acute and Subacute Myelopathies. Clin Neuroradiol 2017; 27: 417-433
• 16 Berlit P. Diagnosis and treatment of cerebral vasculitis. Ther Adv Neurol Disord 2010; 3: 29-42
• 17 Scolding NJ. Central nervous system vasculitis. Semin Immunopathol 2009; 31: 527-536
• 18 Susac JO. Susacʼs syndrome: the triad of microangiopathy of the brain and retina with hearing loss in young women. Neurology 1994; 44: 591-593
• 19 Jennette JC, Falk RJ, Bacon PA. et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65: 1-11
• 20 Nichtweiß M, Weidauer S, Treusch N. et al. White Matter Lesions and Vascular Cognitive Impairment. Part 1: Typical and Unusual Causes. Clin Neuroradiol 2012; 22: 193-210
• 21 Weidauer S, Nichtweiß M, Hattingen E. Differential diagnosis of white matter lesions: non vascular causes – part II. Clin Neuroradiol 2014; 24: 93-110
• 22 Weidauer S, Wagner M, Hattingen E. White matter lesions – a differential diagnostic approach. Fortschr Röntgenstr 2020;
• 23 Weidauer S, Wagner M, Enkirch SJ. et al. CNS Infections in Immunoincompetent Patients. Neuroradiological and Clinical Features. Clin Neuroradiol 2020; 30: 9-25
• 24 Kruit MC, van Buchem MA, Hofman PA. et al. Migraine as a risk factor for subclinical brain lesions. JAMA 2004; 291: 427-434
• 25 Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010; 9: 689-701
• 26 Jäger HR, Gomez-Anson B. Small Vessel Disease – Imaging and clinical Aspects. In: Barkhof F, Jäger R, Thurnher M, Rovira A. eds. Clinical Neuroradiology. Heidelberg, New York, Dordrecht, London: Springer; 2019: 167-201
• 27 Wardlaw JM, Smith EE, Biessels GJ. et al. STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013; 12: 822-838
• 28 Kwee RM, Kwee TC. Virchow-Robin Spaces at MR Imaging. RadioGraphics 2007; 27: 1071-1086
• 29 van der Knaap MS, Bugiani M. Leukodystrophies: a proposed classification system based on pathological changes and pathogenetic mechanisms. Acta Neuropathol 2017; 134: 351-382
• 30 Christoforidis GA, Spickler EM, Recio MV. et al. MR of CNS sarcoidosis: correlation of imaging features to clinical symptoms and response to treatment. AJNR Am J Neuroradiol 1999; 20: 655-669
• 31 Canellas AR, Rovira Gols A, Río Izquierdo J. et al. Idiopathic Inflammatory-Demyelinating Diseases of the Central Nervous System. Neuroradiology 2007; 49: 393-409
• 32 Seewann A, Enzinger C, Filippi M. et al. MAGNIMS network. MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain: A review of reported findings. J Neurol 2008; 255: 1-10
• 33 Wingerchuk DM, Banwell B, Bennett JL. et al. International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177-189
• 34 Eichinger P, Zimmer C, Wiestler B. AI in Radiology: Where are we today in Multiple Sclerosis Imaging?. Fortschr Röntgenstr 2020; 192: 847-853
• 35 Sastre-Garriga J, Pareto D, Battaglini M. et al. MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. Nat Rev Neurol 2020; 16: 171-182
• 36 Geurts J, Roosendaal S, Calabrese M. et al. Consensus Recommendations for MS Cortical Lesion Scoring Using Double Inversion Recovery MRI. Neurology 2011; 76: 418-424
• 37 Riederer I, Karampinos DC, Settles M. et al. Double Inversion Recovery Sequence of the Cervical Spinal Cord in Multiple Sclerosis and Related Inflammatory Diseases. AJNR Am J Neuroradiol 2015; 36: 219-225
• 38 Hodel J, Darchis C, Outteryck O. et al. Punctate pattern – A promising imaging marker for the diagnosis of natalizumab-associated PML. Neurology 2016; 86: 1516-1523
• 39 Yousry TA, Pelletier D, Cadavid D. et al. Magnetic Resonance Imaging Pattern in Natalizumab-Associated Progressive Multifocal Leukoencephalopathy. Ann Neurol 2012; 72: 779-787
• 40 Wattjes MP, Barkhof F. Diagnosis of natalizumab-associated progressive multi-focal leukoencephalopathy using MRI. Curr Opin Neurol 2014; 27: 260-270
• 41 Moll NM, Rietsch AM, Ransohoff AJ. et al. Cortical demyelination in PML and MS – Similarities and differences. Neurology 2008; 70: 336-343
• 42 Gheuens S, Wüthrich C, Koralnik IJ. Progressive multifocal leukoencephalopathy: why grey and white matter. Ann Rev Path 2013; 8: 189-215